Testimonials by Doctors

A. Breast Cancer

A 43 year old woman, Samantha, with Breast Cancer (Grade II) called me on May 17, 2008 when she heard me talk over DZEC's "Basta Natural" Radio Program (Sundays @ 7:15-7:30PM).

Her Pathological Diagnosis: Breast mass, Left, Excision Biopsy: Infiltrating Ductal Carcinoma, Tumor Size: 1.5 cm . Gross and Microscopic Description: The specimen submitted consists of an ovoid, grayish, doughy mass measuring 1.5 x 1.0 x 1.0 cm. Cut sections reveal a brown solid surface RSEB1. Sections of the breast mass reveal an infiltrating ductal mass carcinoma characterized by nests of atypical cells forming minimal tubular structures. These tumor cells feature enlarged vesicular nuclei with prominent nucleoli and scanty eosinophilic cytoplasm. Some nuclei appear hyperchromatic. The stroma shows fibrosis.

The doctors recommended removal of breast by surgery.

After I talked to Samantha on May 20, 2008 , she and her husband decided not to undergo surgery nor chemotheraphy, but just take transfer factor and so I gave a mega dose of : Transfer Factor Tri-Factor Plus (3 caps 3 x a day), Transfer Factor Tri-Factor Formula (2 caps 3 x a day) and TF Riovida (30 ml 3 x a day).
On August 2, 2008 (less than 3 months only) her ultra sound shows an amazing Cancer Free result. (Please see lab test results below)

Today, Samantha is all out helping others get back their health by promoting Transfer Factor likewise. Her first patient was cured of COPD (Chronic Obstructive Pulmonary Disease) after 2 months.
The rest is history.



Before Transfer Factor (April 2008). Click photo for an enlarged version.


Cancer-free after Transfer Factor (August 2, 2008). Click photo for an enlarged version.


B. Prostate Cancer, Stage 4

An 82 year old man was dying (1 week to live in NKI) in 2005 due to Stage 4 Prostate Cancer, with metastasis in the lungs plus Severe Pneumonia. All three doctors signed a waiver because it was the end of the line. I gave this man Transfer Factor Plus 4 caps 3 x a day, Transfer Factor Advanced 2 caps 3 x a day and TF Riovida 40 ml 3 x a day. He could not take anything by mouth so we gave Transfer Factor via NGT and also via sublingual, wiping the tongue and areas around it daily. Amazingly, in just 11 days, he stood up and walked home. In 3 months he was declared Cancer-Free as proven in the MRI test. Today, after 4 years, I checked on him and he is enjoying fishing and living the good life.

C. Cystic Breast

A 40 year old woman from General Santos with a cyst in her breast below the nipple took Transfer Factor Plus 2 capsules 3 times a day and in two days the cyst dissolved completely. She took it one hour before every meal and she practiced sleeping at 11pm with lights off. Then after two days she was amazed that the cyst was gone.

D. Click to Read Testimonial on Breast Cancer, Stage II-B 

E. Atopic Dermatitis (a.k.a Skin Asthma or Atopic Eczema)

A 21-year old woman who suffered from severe atopic dermatitis, a chronic infammation of the skin, also called atopic eczema, was told by her array of doctors from various hospitals that there is really no cure for it. However, her dad heard my interview on Transfer Factor over DialM Channel 4, and immediately went to see me last Oct 18, 2008. She started taking Transfer Factor Tri-FactorFormula : 2 capsules 2 x a day before each meal. In just 21 days she recovered. Now she's taking TF as maintenance supplement. Truly it was life changing as she's back to work. On top of that, as bonus she became a commercial model and an actress as her skin became so beautiful.

F. Stroke

Angelito, 46 Year old man from Zamboanga del Sur, suffered stroke on June 19, 2010. He was half-body paralyzed and could not talk. He was confined in a hospital in Cebu City and immediately a friend by the name of Jun E. went to visit him and gave him TF Riovida (30ml 2 x a day) and TF Cardio (4capsules 2 x a day). After 2 days, he stood up, talked like a normal person so he was discharged on the 3rd day June 22. Truly the product worked so fast.

G. Leukemia

A 21 year old woman from Palawan with Stage 1 Leukemia took Transfer Factor Cardio with only 2 capsules a day and after one month, she was declared healthy and leukemia-free.

H. Leprosy & Skin Asthma/ Others

TRANSFER FACTOR is very effective adjuvant as Supportive Therapy for Leprosy Patients who are WHO, World Health Organization, Drug Resistant Case with Lepra Reaction and those suffering from Severe Skin Asthma according Dr. Ma. Luisa Abad-Venida, M.D., FPDS,- Consultant Dermatologist, Former Chair of the Department of Dermatology, JOSE REYES MEMORIAL MEDICAL CTR &; PRESIDENT of the SKIN RESEARCH FOUNDATION OF THE PHIIPPINES. [You may contact her at her Clinic- Telephone:(632)7116703, 9205041 or 9217252, Mobile: (63)9178173065]

Dr. Venida has tested Transfer Factor in combination with prescribed medication on several leprosy and severe skin asthma patients and she can attest to its effectiveness in improving the effects of standard therapeutic regimen. So Transfer Factor must be used in combination with approved regimen.

CASE STUDIES USING TRANSFER FACTOR ON LEPROSY WITH LEPRA REACTION
BY DR. MA. LUISA ABAD-VENIDA, M.D.

Dx. Lepromatous Leprosy,
WHO Drug Resistant Case
C.,21 yr old male
Tx.
Lymecycline 30 mg bid
Transfer Factor Plus 9 capsules a day

The Use of Transfer Factor in Lepra Reaction by Dr. Ma. Luisa Abad-Venida, M.D.

Introduction:
The decline in registered prevalence of leprosy worldwide stimulated the recent policy changes within the World Health Organization. The emphasis was shifted from tackling leprosy as a public health issue to sustaining quality services for people affected by the disease; to prevent deformities and thus remove the stigma attached to it. Deformities in leprosy are due to lepra reaction that damages the peripheral nerves leading to paralysis of the affected muscle or loss of function of skin appendages. Lepra reaction may occur before treatment, but more so during treatment and continuing intermittently or continuously until the body has totally eliminated the mycobacterium debris from the body. Prompt and proper treatment of lepra reaction is critical in preventing deformities. The most common treatment option available is corticosteroid that acts as T-cell suppressor(1,2,3,4,5) Although steroid is very effective in treating lepra reaction, its chronic use in cases of severe lepra reaction poses the problem of further compromising the cell mediated immunity status of patients in the lepromatous spectrum, encouraging emergence of resistant strains and/or the accompanying problem of steroid toxicity.

In the Philippines, absenteeism and default still continue to be a problem. Multidrug therapy (MDT) for leprosy containing rifampicin, dapsone and clofazimine should be taken continuously for 12 blister packs to ensure near adequate treatment. Drug resistance could emerge rapidly among patients whose treatment regimens were inappropriate. To date, all the official multi-drug therapy contain rifampicin (RMP), which is significantly more bactericidal than any other anti-leprosy drugs or any combination of ofloxacin, clarithromycin and minocycline.(6) Emergence therefore of RMP- resistance would create tremendous difficulty for the treatment of individual patient, and its dissemination would pose a serious threat to the achievement of leprosy control. Multiple resistance to Dapsone (DDS), RMP, and Ofloxacin (OFLO) have also been reported. (7) Problems of logistics, compliance, drugs resistance and drugs toxicity point to an urgent need for alternative approaches like immunotherapy to shorten current treatments. A potential immunotherapeutic agent is Transfer Factor. Discovered by Dr. H. Sherwood Lawrence in 1949(8), “An evaluation of Transfer Factor as immunotherapy for patients with lepromatous leprosy “was reported by Ward E. Bullock, M.D. in 1972 using human lymphocytes from sensitized donors. He concluded that delayed hypersensitivity reaction to M.leprae antigens can be produced, with lymphocytes or their extracts, in patients with anergic leprosy.(9) In mid 1980’s, two researchers discovered the presence of Transfer Factor in colostrums and later in egg yolk, that led to its availability in oral form. “Combination of drugs and Transfer Factor in the treatment of leprosy” has been shown to enhance bacterial killing and clearance, reported by Katoch K in 1986.(10)
The use of Transfer Factor led to the successful recovery of the three cases of severe lepra reaction that have already completed MDT treatment.

CASE REPORTS
Case 1

A 15 year old male child from Malabon City, in type II lepra reaction, was diagnosed with lepromatous leprosy in 2003 at the age of 12 years old, with an average bacteriologic index (BI) of 4.6+, was given MDT on 1Jan03-31May03 and 17Jun05-30April06. Lepra reaction developed on his 2nd month of MDT, corticosteroid was started following the WHO recommendation. His intake of steroid beyond 12 weeks was either prescribed or as self medication. He was also prescribed NSAIDs, Colchicines and Squalene.(fig 1.1) Between May 2004 BI 2.8+ and May05 BI 2.6 with slackened drop in average BI and chronic use of steroid, coupled with high WBC 32.38 and high alkaline phosphatase 270 (44-155) it was deemed necessary to reinstitute another course of MDT under close monitoring. In March 06, there was worsening of the symptoms manifested as high grade fever 39C, joint pains, body malaise, increased erythema, swelling of digits of both hands and elevation and tenderness of plaques. There was also muscle weakness as he was incapable of feeding himself and writing his assignment.(fig.1.2 and 1.3)
With a BI 1.4+, an impression of steroid toxicity and or dapsone syndrome with lepra reaction required hospitalization, discontinue all medications and initiate supportive therapy. Transfer Factor 600mg TID was started initially, on his 3rd hospital day, joint pains disappeared together with body malaise and fever. Plaques and hand swelling gradually diminished and he was discharged after 5 days confinement. Home medications were Transfer Factor in supervised doses, Vitamin B complex, colchicines and petroleum jelly. Patient condition continued to improve after consuming 108,000 mg pure Transfer Factor and 54,000 mg plus cordyvant Transfer factors.(fig 1.4) AFS turned negative in 2007.

Case 2 (See Treatment Graph Above)

A 21 year old male from Bulacan, was diagnosed with lepromatous leprosy in 2004. His condition started as numbness on the R elbow 15 years prior to consult (PTC) but did not sought treatment. He was 13 years old when he was given MDT-MB but took only 3 blister packs and stopped because of improvement. For about 3 years PTC, he was suffering from increasing number of patches in his body and appearance of nodules on the face and earlobes before finally coming to our institution, and, with his younger brother who has the same problem.
His average BI 4.5+, highest on R earlobe 6+ solid, on admission, persisted from 4Nov04-25Sept05 until the end of his regular MDT-MB treatment. At this time, he complained of myalgia, dizziness and easy fatigability. CBC revealed severe anemia Hgb 77. Drug resistance to MDT and/or Dapsone syndrome was considered and so Ofloxacin 400mg OD 5Sept05-3Feb06 (fig 2.1) was added to his regimen with clofazimine 200mg daily in tapering dose with Dapsone was removed from the regimen.
He developed lepra reaction during his 2nd blister pack and was prescribed corticosteroid following the WHO recommendation, NSAIDs and colchicine plus supportive medications of aluminum MgSO4, Vit D, Calcium and B complex. (fig 2.2) His signs and symptoms were generalized erythematous plaques, nodules, vesicles, ulcers, crusting, joint pains, nerve tenderness and fever.
In Feb 2006, with a persistently high average BI 4.5+ (fig 2.1) despite the 5 months treatment of Modified MDT-MB, and worsening skin lesions, accompanied by chills and fever, joint pains and deteriorating liver function SGPT 68.5(0-38) and SGOT 222.9(10-40) it was recommended by Internal Medicine to totally discontinue present Modified MDT medications. Multiple drug resistance was considered with lepra reaction. Alternative drugs were given in Mar 06 namely Transfer Factor 300mg with cordyvants TID and Lymecycline 600mg OD for 4 months. Solid M. leprae bacillis on smears became granulated after 1 month dose and thereafter. (fig 2.3) Prednisone was tapered till 5mg every other day but self- medicated as necessary, when new ENL lesions and joint pains were noted occasionally. There was also irregular intake of Transfer Factor because of financial constraints. In Nov 07, noting the presence of one solid bacilli on smear, and an average BI 4+, he was given another 3 months course of Lymecycline 600mg OD together with more regular intake of full doses of Transfer Factor Plus cordyvant. AFS as of Feb 08 was average BI 1+. ( fig 2.4). The patient will be maintained on Transfer Factor 300mg TID plus cordyvant till AFS negative. As of this writing, he still suffers of few ENL lesions. (fig 2.5)


Case 3

A 22 year old male from Bulacan was diagnosed with Borderline leprosy in type II lepra reaction in 1Mar06. He was given MDT-MB treatment from 4April06-8March07 and Prednisone 40mg following the WHO recommendation with Clofazimine, Colchicine, Extra virgin coconut oil (EVCO), and Ranitidine. He was never totally off prednisone when in Oct. 30, 2007, he was brought to JRRMMC, wheelchair borne, unable to walk because of severe pain and swelling of both feet with deep necrotic ulcers. (fig 3.1) There was also ulceration on his knee. There was associated nausea and L abdominal pain. His baseline AFS was average BI 3+ and Ave. BI 2+ at the end of MDT-MB treatment.
His diagnosis was Lucio Phenomenon, released from treatment (RFT). Transfer factor 300mg TID plus cordyvants was prescribed as well as gradual tapering of steroid. Debridement with sandwich dressing was done on 2 weekly follow-ups and he was able to walk and go up the stairs on his 3rd week. His latest ave.BI is .5+ as of Feb08. He will continue to take transfer factor plus until he is AFS negative and aim at removing prednisone 5mg q2d as security blanket treatment.

DISCUSSION
Advances in civilization, scientific and technical progress, achievements in medicine, have not helped reduce infectious diseases; rather there are newer groups of infections that are attacking people. Leprosy, a disease known to men, existing even before Christ have long been recognized to be due to poor cellular defense against Mycobacterium leprae among advanced stages. 90% of Filipino patients with leprosy suffers from the multibacillary form of the 2,517 new cases detected in 2006, which brings to fore the high possibility of leprae reaction to 50%.

Multi-drug therapy (MDT), a regimen recommended by WHO was introduced in the Philippines in 1982. Despite very encouraging reports on MDT, nerve damage and disability in leprosy still occurs and this is induced by lepra reaction. It has been estimated that at a global level, there may be 3 million people with leprosy related impairments and disabilities.
The problem of logistics, compliance, drug intolerance and side effects to MDT-MB treatment, points to an urgent need for a supportive approach like immunotherapy. Immunotherapy has been found to shorten the course of treatment and clearance ensuring early relief from lepra reaction.
Lepra reactions are episodes of sudden increase in the immune activity of the disease versus the host. There are 2 forms of lepra reaction, type I being less severe compared to type II lepra reaction that occurs in multibacillary forms. The treatment of reactions is based on suppression of inflammation and WHO recommends the use of prednisone to do this.A high dose of prednisone 40-60mg daily taken for 12 weeks may result in several undesirable effects. These are Cushing’s syndrome, steroid induced diabetes, osteoporosis, hypertension, psychosis, depression, striae and increased susceptibility to infection especially tuberculosis. It has been reported that in borderline (BB) treatment of lepra reaction takes weeks, borderline-lepromatous (BL) wks and lepromatous leprosy (LL) wks. In these patients, there is high antibody response and the dominant cytokine circulating in their body are IL4 which promotes B cell growth and differentiation and IL10 which inhibits ThI cytokine production. Leprosy is one of infectious diseases that manifest the Th1-Th2 paradigm shift with progressive evolution of the disease from tuberculoid (TT) form exhibiting the Th1 status to lepromatous (LL) form exhibiting the Th2 status. With this basic information in mind, an important enhancement against M.leprae in our general immune system should be one of our therapeutic goals.

Transfer Factor as was used to supplement the treatment in these 3 cases has been used to effectively treat a wide range of diseases. Transfer Factor is an immune modulator. The main function of these peptides in the body is to provide immune protection against microbes (bacteria, viruses, fungi, protozoa), cancerous cells and other antigens capable of disturbing vital processes in the body. It stimulates the cellular arm of the immune system (killer lymphocytes), activates immune cytokine synthesis and regulates immune function. An evaluation of Transfer Factor as immunotherapy for patients with lepromatous leprosy was first used by Bullock, using whole lymphocytes from donors with delayed hypersensitivity to antigens of mycobacterium leprae were employed to reconstitute delayed hypersensitivity in nine patients with anergic leprosy. Six of seven converted from anergy to delayed hypersensitivity response to m. leprae antigens. Two of 3 patients showed an increase in perivascular lymphocytic infiltration in the post-transfer skin test biopsy site. Delayed hypersensitivity reactions to M. leprae antigens can be produced, with lymphocytes or their extracts, in patients with anergic leprosy. In a study by Fabre of Mexico, in his study of Transfer Factor as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis. When BALB/c mice are infected via trachea with M. tuberculosis, H37Rv, there is an initial phase of partial resistance dominated by Th-1 type cytokines plus tumor necrosis factor-alpha (TNFa) and the inducible isoform of nitric oxide synthetase (iNOS) followed by a phase of progressive disease characterized by increasing expression of IL-4, diminished expression of TNFa and iNOS and low DTH. Animals in this late progressive phase of the disease were treated with different doses of transfer factor ( one injection per week) obtained from spleen. The peak of immune protection in this animal model is reached on day 21(11)
Since its discovery by Sherwood Lawrence, more than 50 years ago, the therapeutic and prophylactic applications have been most important and interesting aspects of Transfer Factor. It has been found to be very effective in those diseases in which CMI plays a relevant role in protection and control of the disease , such as viral infections (herpes simplex, varicella zoster), intracellular bacterial diseases (tuberculosis, leprosy) and parasitic infections (leishmaniasis, toxoplasmosis), as well as in immunodeficiencies (chronic granulomatosis, Wiscott Aldrich syndrome and some types of cancer. Transfer Factor (TF) are protein that transfer the ability to express cell mediated immunity from immune donors to non-immune recipients. TF treatment were found to selectively affects cytokine production in response to antigenic stimulation.(12)
Transfer factors are tiny molecules also found in colostrum which provides immune knowledge from mother’s immune system to her baby used in fighting outside threats. By transferring information from cell to cell, transfer factors serve as “teacher” to the new cells, ensuring a strong immune system capable of surviving, and thriving in its new environment. Transfer factor are not species-specific and can therefore be extracted from any mammal and then be given to another mammal with the same efficacy. Transfer factor naturally supports the body’s immune system, communicating immune information more efficiently among the cells in the body, and ultimately enhancing the body’s ability to withstand attacks on its health.
Transfer Factor TM was tested for its ability to increase Natural Killer Cell (NK) activity. Peripheral blood mononuclear cells (PBMC) isolated from human volunteers showed boosting of NK cell activity by 103% above normal immune response. NK cells are important in strengthening and supporting the immune system . In advanced stage leprosy (LL)where there is poor to absent CMI activity, it was found by Bullock, etal the positive effect of Transfer factor in anergic leprosy, it was also found by Katoch etal the early clearance of bacilli in LL patients given MDT and Transfer Factor.

Conclusion:
The positive effect of Transfer Factor TM in treating Lepra reaction (case 1), combination with Lymecycline , a second generation cycline that is as effective as minocycline in treating RMP and OFLO resistance (case2) and in treating Lucio phenomenon, a very severe form of lepra reaction makes this food supplement a good material for clinical research. Transfer Factor TM, was found to be safe in oral form , has no adverse reactions and is effective in both children and adults in treating lepra reactions It was also found to enhance bacterial clearance.
References:
1). WHO Expert Committee on Leprosy. Seventh Report. WHO Technical Report Series No. 874. World Health Organization, Geneva, 1998
2). Briton, WJ. The management of leprosy reversal reactions (Editorial). Lepr Rev, 1998: 69: 225-234.
3). Rose P, Waters MF, Reversal reactions in leprosy and their management (Editorial). Kepr Rev, 1991; 62: 121-131.
4). Naafs B. Treatment of reactions and nerve damage. Int J Lepr, 1996: 64:S21-28.
5). Becx-Bleumink M, Berhe D. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy: experience in the Leprosy Control Program of the All Africa Leprosy and rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr, 1992; 60: 173-184
6). Ji, B., E. G. Perani, C. Petinom and J. H. Grosset. 1996 Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrob Agents Chemother, 42(1998)1115-1120. 2. JI, B., etal Bactericidal activities of combination of new drugs against mycobacterium leprae in nude mice. Antimicrof.Ag Chemother, 40:393-399.
7). Ji, B., P. Jamet, S. Sow, E.G. Perani, I. Traore, and J.H. Grosset. 1997 High relapse rate among lepromatous leprosy patients treated with Rifampicin plus Ofloxacin daily for 4 weeks. Antimicrob Agents Chemother, 41: 1953-1956.
8). Lawrence H.S. The transfer in humans of delayed skin sensitivity to streptococcal M substances and to tuberculin with disrupted leucocytes.1955 J Clin Invest. 34:219-30.
9). Bullock, W.E., Fields, J.P. amd Bandvias M.W.1972 Am evaluation of transfer factor as immunotherapy for patients with lepromatous leprosy. New Eng J Med. 287:10-53.
10). Katoch 1986 Combination drug therapy
11). Fabre R A, Perez T M, Aguilar, L D, Rangel M J, Estrada-Garcia I, Hernandez-Pando R, and Estrada Parra S. Transfer factors as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis 2004 Clin Exp Immunol 136(2): 215-223.
12). Alvarez-Thull L, Kirkpatrick C H. Profiles of cytokine production in recipients of transfer factors. 1996 Biotherapy 9(1-3) 55-9
13). Fitzpatrick etc

I. HIV/ AIDS

ABSTRACT
Usage of transfer factors in treatment of HIV-Infected Patients
Granitov V.M., Karbysheva N.V., Sultanov L.V., McCausland C., Oganova E.
The Altay State Medical University;
The Altay Regional Center for Prophylaxis and Treatment of AIDS, Russian Federation

INTRODUCTION: Included in this study were 25 HIV-infected patients (20 male and 5 female), ages 19 to 56 (15 patients ages 21-25). Individuals were classified according to V.I. Pokrovsky’s classification (1989) for HIV-infection. Eight (8) patients were diagnosed to have stage 2B, thirteen (13) patients were stage 2C, three (3) patients were stage 3A and one (1) was stage 3B. Infection periods were as follows: nine (9) patients were infected 1 year ago, four (4) were 2 years ago, four (4) were three years ago, six (6) were 5 years ago and two (2) were 6 years ago.

OBJECTIVE: The purpose of this study is to serve as an initial trial in evaluating the effects of enhanced transfer factors supplementation on HIV-infected patients.

METHODOLOGY: The experimental group (15 patients), who did not receive antiretroviral or immuno-correcting therapy, received enhanced transfer factors provided by 4Life Research, USA. They were administered one capsule twice a day for 7 days. The control group (10 patients) consisted of HIV-infected patients taking cycloferon in the following dosage schedule: 1st, 2nd, 4th, 6th, 8th, 10th, 12th and 14th days. Before treatment and 7 to 10 days after the treatment an evaluation was carried out to access the immune status of the patient groups and to determine cytokine (interleukin 1b (IL-1b), tumor necrosis factor (TNF-a) and g-interferon (IFN-g) levels.

RESULTS: In the experimental group, it was found that after treatment with enhanced transfer factors there was an increase of lymphocytes in 13 patients, an in crease of CD3 cells in 15 patients, an increase of CD4 cells in 14 patients and an increase in CD8 cells in 12 patients. Immuno-regulating index (IRI) persisted on the same level in 3 patients was increased in 10 patients and decreased in 7 patients. IgG was reduced in 16 patients and IgM was within normal limits in all patients. An increase of IL-1b and IFN-7 was noted in all patients treated with transfer factors. Circulating Immune Complex (CIC) levels dropped to normal levels in 10 of the patients. In the control group an increase of lymphocytes was noted in only 3 patients. A decrease of CD3, CD4 and CD8 cells was noted in 6 patients. IRI persisted on the same level or decreased. CIC levels dropped to normal in 3 patients, increased in 6 patients, there was no change in 1 patient. The occurrence of increases and decreases of IgG were equal.

CONCLUSION: We conclude that transfer factors therapy considerably improves the immune status of HIV-infected patients and can be recommended in combating the pathogenesis of the disease. Further studies are needed to determine optimal therapy, the necessity to repeat courses of the treatment and the frequency of therapy needed.

In its Methodoligical Letter (Moscow 2004), The Ministry of Health and Social Development of the Russian Federation published the following :

"Acquired Immunorehabilitation Syndrome (AIDS) is one of the most serious problems confronting medicine. For HIV patients immune modulation therapy (i.e. the restoration of normal immune function) is aimed altered immune mechanisms and at the pathogenic agent(s).


The results of studies conducted showed that TRANSFER FACTOR (TF) PLUS treatment significantly improved the immune status of HIV patients. The product also proved useful in other aspects of therapy as for example the level of circulating immune complexes (CIC) decreased to normal values in 50% of patients receiving TF PLUS."


In the XIth International Congress on TransferFactor held in Monterrey Nuevo Le
on, Mexico, 1999, an article below was presented:


TITLE: 25 YEARS OF CLINICAL EXPERIENCE WITH TRANSFER FACTOR

AUTHORS: Giancarlo Pizza, Caterina de Vinci, Aldopaolo Palareti, Dimitri Viza

INSTITUTION: Immunotherapy Unit, Div. of Urology, S. Orsols-Malpigi Hospital Bologna, Italy

ABSTRACTS:

Patients. From April 1974 to Hanauary 1999, using TF produced in our laboratories, we treated a total of 1647 patients (pts) suffering from persistent viral infections viz. hepatitis, herpes, herpes zoster, giant condyloma acuminatum, conjunctivitis, herpes keratitis and keratouveitis, (439 pts), cancer, viz. Prostate, lung, renal metastatic, transitional cell carcinoma of the bladder (TCCB), EBV-related naso-pharyngeal carcinoma (NPC), gastrointestinal (GIT), ovary, uterus, Burkitt's lymphoma, breast, glioblastoma (643 pts), recurrent cystitis and candidiasis (287 pts), chronic fatigue syndrome (74 pts). AIDS (51 pts) and /or various congenital and (/or autoimmune disorders, e.g. retinitis pigmentosa, chorioretinitis, uveitis, Bechet's syndrome and Lapeyronie's disease (153 pts)."

Reference: www.biotransfer.org

In the ABSTRACTS OF THE COMMUNICATIONS PRESENTED AT THE XTH INTERNATIONAL SYMPOSIUM ON TRANSFER FACTOR, HELD IN BOLOGNA (ITALY) JUNE 22-24, 1995:

"AIDS AND TRANSFER FACTOR: MYTHS, CERTAINTIES AND REALITIES"
by Dimitri Viza

Laboratoire d'Immunobiologie, URA 1294 CNRS, Faculté de Médecine, Paris, France

At the end of the 20th century, the triumph of biology is as indisputable as that of physics was at the end of the 19th century, and so is the might of the inductive thought. Virtually all diseases have been seemingly conquered and HIV, the cause of AIDS, has been fully described ten years after the onset of the epidemic. However, the triumph of biological science is far from being complete. The toll of several diseases, such as cancer, continues to rise and the pathogenesis of AIDS remains elusive.

In the realm of inductive science, the dominant paradigm can seldom be challenged in a frontal attack, especially when it is apparently successful, and only what Kuhn calls "scientific revolutions" can overthrow it. Thus, it is hardly surprising that the concept of transfer factor is considered with contempt and the existence of the moiety improbable: over forty years after the introduction of the concept, not only its molecular structure remains unknown, but also its putative mode of action contravenes dogmas of both immunology and molecular biology. And when facts challenge established dogmas, be in religion, philosophy or science, they must be suppressed. Thus, results of heterodox research become henceforth nisi - i.e., valid unless cause is shown for rescinding them, because they challenge the prevalent paradigm. However, when observations pertain to lethal disorders, their suppression in the name of dogmas may become criminal. Because of the failure of medical science to manage the AIDS pandemic, transfer factor, which has been successfully used for treating or preventing viral infections, may today overcome a priori prejudice and rejection more swiftly. In science, as in life, certainties always end up by dying and Copernicus' vision by replacing that of Ptolemy."

Reference: http://www.biotransfer.org/art03.html


J. CLINICAL STUDIES : TRANSFER FACTOR AS IMMUNOTHERAPY AND SUPPLEMENT OF CHEMOTHERAPY IN EXPERIMENTAL PULMONARY TUBERCULOSIS

AU: R. A. FABRE, T. M. PÉREZ, L. D. AGUILAR, M. J. RANGEL, I. ESTRADA-GARCÌA, R. HERNÁNDEZ-PANDO, S. ESTRADA PARRATI: Transfer factors as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis
SO: Clinical & Experimental Immunology
VL: 136
NO: 2
PG: 215-223
YR: 2004
ON: 1365-2249
PN: 0009-9104
AD: Department of Immunology, National School of Biological Sciences, National Polytechnical Institute and ; Experimental Pathology Section, Department of Pathology, National Institute of Medical Sciences and Nutrition Salvador Zubirn, Mxico
DOI: 10.1111/j.1365-2249.2004.02454.x
US: http://dx.doi.org/10.1111/j.1365-2249.2004.02454.x
AB: Problems of logistics, compliance and drug resistance point to an urgent need for immunotherapeutic strategies capable of shortening the current six month antibiotic regimens used to treat tuberculosis. One potential immunotherapeutic agent is transfer factors. Transfer factors (TF) are low molecular weight dialysable products from immune cells which transmit the ability to express delayed-type hypersensitivity (DTH) and cell mediated immunity from sensitized donors to nonimmune recipients. In this study we determined the efficiency of TF as immunotherapy to treat experimental tuberculosis. When BALB/c mice are infected via the trachea with Mycobacterium tuberculosis H37Rv there is an initial phase of partial resistance dominated by Th-1 type cytokines plus tumour necrosis factor-alpha (TNF03B1) and the inducible isoform of nitric oxide synthase (iNOS), followed by a phase of progressive disease characterized by increasing expression of IL-4, diminished expression of TNF03B1 and iNOS, and low DTH. Animals in this late progressive phase of the disease (day 60) were treated with different doses of TF (one injection per week) obtained from spleen cells when the peak of immune protection in this animal model is reached (day 21), or with different doses of TF from peripheral leucocytes of PPD + healthy subjects. We show here that the treatment with murine or human TF restored the expression of Th-1 cytokines, TNF03B1 and iNOS provoking inhibition of bacterial proliferation and significant increase of DTH and survival. This beneficial effect was dose dependent. Interestingly, murine TF in combination with conventional chemotherapy had a synergistic effect producing significant faster elimination of lung bacteria loads than chemotherapy alone.

MORE CLINICAL STUDIES

The following five articles are from the IX National Congress of Dietologists and Nutriologists that took place in Moscow, Russia December 3-5 and published in Nutrition and Health. This National Scientific Practical Conference of Pediatric Nutritionalists was a divisional meeting of the Russian Academy of Medical Sciences.

I. Transfer Factor Classic Effectiveness in the Treatment of Patients with Opthalmotoxoplasmosis.
G.K. Zhumanbayeva, G.U. Alshinbayeva, M.G. Portnova, K.M. Baygabulova, I.N. Losiev, B.B. Utegenova, E.S. Seitakhmet. “Zhurek” clinic, Karaganda

We used a systemic approach to analyze the dynamics changes in patients treated for Opthalmotoxoplasmosis. The 1st group patients after receiving the regular treatment medicine (rovamycin) did not manifest any significant changes in immune index correlations, except there was a significant increase in the neutrophilic immunity index that increased by 33.3%. Interrelations of immunity displayed a moderate degree of significance (28.6%, r≥0.5). After receiving Transfer Factor Classic in combination with rovamycin, the number of statistically significant correlations of immune index increased by 57.1% and the number of statistically significant interrelations in neutrophil index increased to 47.6%. Correlations with only a moderate degree of significance (r≥0.5) occurred in 48% of the total number of all interrelations in this group. The 2nd group received Transfer Factor Classic in addition to rovamycin. This treatment regime proved especially beneficial to those with neurotoxoplasmosis and visual impairment, when compared to other existing methods of treatment, which are far less effective in these espects. The analysis performed after the combined treatment demonstrated a significant improvement in 87.5% of patients and moderate improvement in 12.5% of them. The combined treatment (rovamycin and Transfer Factor Classic) significantly increased the number of leukocytes by 21.5% with neutrophils up 31.1%; the number of T-lymphocytes increased by 46.1%; the content of “zero” lymphocytes decreased by 27.1% due mainly to the increase of T-helpers by 40.9%. The combined data for the group showed phagocytic activity of neutrophils increased by 52.3% and IgG level increased by 36.8%. The inclusion of Transfer Factor Classic also contributed to positive dynamics of primary, secondary, intermediate, summary and end point peroxide lipid oxidation (PLO) products (excluding ketodiens) and in restoring patients’ values to those of nominally healthy people. Thus, according to the dynamics of PLO-АОS (peroxide lipid oxidation - antioxidative system).

We concluded that this regiment of combined treatment, which includes Transfer Factor Classic, is the most effective method of opthalmotoxoplasmosis treatment that we have experienced in our clinic.

II. The Use of Transfer Factor as Alimentary Support of Specific Chemotherapy in Primary Multiresistant Tuberculosis.
I.G. Tsoy, A.M. Yesengelgiyeva. Kasakh Academy of Nutrition, Alma-Ata

Transfer Factor, a versatile natural peptide immunocorrectors, at oral dosages of 1 capsule 3 times daily for one month and Transfer Factor Plus at 1 capsule 3 times daily for one month was used in the treatment of patients suffering from primary drug resistant pulmonary tuberculosis
to such second line drugs as capreomycin, protionamid, ofloxacin, cecloserin. The patients demonstrated a significantly earlier disappearance of signs of toxification, cough, symptoms of respiratory failure and an acceleration of the process of temperature normalization.

The cessation of bacterial release, return to normal ESR (erythrocyte sedimentation rate) and moderation of leukocytosis were all of shorter duration as well. Frequency of the reparation process, development and resorption of pulmonary tissue infiltrates as well as shrinking and closure of decomposition cavities indicate the positive effect of this alimentary immunocorrector. With it we managed to eliminate the existing deleterious changes that had occurred in liver function and also to prevent the development of adverse reaction of intestinal microbiocenosis to these second line antituberculous drugs.

The use of Transfer Factor products contributed to the increase of what was an initially low numbers of CD3+ and CD4+ T cells, the number of T-regulatory and cytotoxic cells (CD8+) also changed significantly. The changes in the number of immunoregulatory T-cells resulted in significant increase in the initially low mean value of quantitative immunoregulatory index (CD4+/CD8+). In the test group the relative number of NK-cells (CD16+) reached those of the
control group. In most cases there were no statistically significant changes in the number of B-lymphocytes, which values being slightly elevated. According to the data of the leukocytes migration inhibition reaction there was a distinct increase in delayed sensitivity to tuberculin,
which was especially noticeable in the dynamics of the individual values. While evaluating humoral immunity we noted that the use of alimentary immunocorrectors contributed to the decrease of initially high levels of IgA, IgM and IgG, with the IgG numbers decreasing the most
significantly. As to the phagocytic system the neutrophilic leukocytes (NST-test) demonstrated greater bactericidal reserve.


III. The Role of the Biologically Active Supplement Transfer Factor in Increasing Preoperative Polychemotherapy Effectiveness in Breast Cancer and in Decreasing Side Effects.

I.G. Tsoy, M.I. Saktaganov, Kazakh Academy of Nutrition, Alma-Ata

We used Transfer Factor, a biologically active supplement produced by 4Life company, USA at dosages of 1 capsule 3 times daily for 1-3 courses of treatment in conjunction with aggressive polychemotherapy treatment of breast cancer patients. We used it to determine if it would decrease the major side effects (immunohematological effects in particular). A control group of matched subjects in age and clinical forms of the disease did not receive Transfer Factor.

The use of the transfer factor immunocorrector markedly contributed to the decrease in the frequency and the severity of common polychemotherapy complications such as toxification, nausea, vomiting, anorexia, taste change and intestinal function disturbances. The dynamics, as indicated by total blood count, showed a distinct protective effect of the Transfer Factor on red blood (erythrocytes number, hemoglobin, serum iron and ESR levels) and white blood (leuko- and lymphopenia) cells. As compared to the control group the test group patients also demonstrated less frequent and less pronounced polychemotherapy complications in terms of liver function (ALT, AST, GGT and gamma-glutamyltransferase), kidney function (total urinalysis, creatinine and urea levels), and chronic pyelonephritis aggravation and other functions and in blood serum total albumen and its fractions.

According to immunological monitoring assays the test group experienced a smaller decrease of relative and absolute number of total T-lymphocytes (CD3+) circulating in peripheral blood along with their helper-inductor subpopulation (CD4+) and cells expressing receptors to IL-2 (CD25+). The increases in T-lymphocytes of suppressors and killers phenotype (CD8+) in the test group are attributable to protective effect of Transfer Factor. The ratio CD4+/CD8+ (conventional quantitative immunoregulatory index) of the test group decreased less that for the control group during the course of polychemotherapy. Also, the decrease of natural killer cells (CD16+) in peripheral blood resulting from chemotherapy was less pronounced in the patients
receiving the immunoregulating transfer factor peptides. A protective effect by transfer factor on T-helpers’cell non-specific functional activity was also demonstrated in the results from the inhibition reaction of leukocytes’ migration by PHA-R (phytogemagglutinin). In the test group the levels of the main classes of immunoglobulins experienced less hypoimmunoglobulinemia,
another indicator of the immunoprotective effect of Transfer Factors.



IV. Clinical and Immunological Effectiveness of Transfer Factor in the Treatment of Gestation Pyelonephritis.

O.G. Tsoy, V.V. Tian, G.U. Akhmed’anova, Sh.V. Abdugalimov. Kazakh State Medical Academy, Astana


The study group consisted of fifteen (15) pregnant women (gestation period 28 weeks) with gestational pyelonephritis (acute, aggravated chronic) that were treated in the pregnancy pathology department of the 1st City hospital. The immunomodulator Transfer Factor™, a biologically active supplement (BAS) produced by a USA company 4Life, was used in the study. The regiment included 1 capsule of Transfer Factor™ 3 times daily for 10 days in the treatment complex.

The clinical and immunological effectiveness of Transfer Factor was confirmed in both clinical laboratory analyses and specific immunological investigations. There was statistically significant increase of absolute number of total lymphocytes (p<0.001)>.


V. Transfer Factor is a Modifier of Biological Age
A.G. Chizhov, V.A. Santalova Russian People’s Friendship University, Moscow

There is a close link between the decrease of functional activity of the immune system and aging. Thus, we decided to study immunomodulators to determine to what extent they may
affect biological age indices. A new immune theory of aging (V.I.Dontsov, V.N. Krut’ko, 2002) points to the role of specific T-lymphocytes subpopulations in sustaining a certain level of normal cellular growth in the body and dwells on the importance of their functional decrease having
a strong impact on aging. Stimulation of the function of these cells by Transfer Factor (TF), an immunomodulator produced by 4Life, USA, seemed a plausible method of “treating aging”. The evaluation of the role TF in the process of aging is at the basis of this study.

Twelve (12) men aged 55-73 were included in the study. A dose of 300 mg. of the TF product was given daily with meals 5 times a week for 6 weeks. Biological age was determined
using the “АPK” method (“Diagnostics of aging: biological age” (National gerontology center, Moscow)). The following biomarkers were used for making the determinations: AP (arterial pressure), pulse wave velocity, VC (vital pulmonary capacity), static balance, Shtange’s test,
adaptation testing, body mass, left hand strength, Shulte’s test, Veksler’s test, neuromuscular test, hearing frequency threshold and the SAN’s questionnaire. The functional activities of body systems were evaluated by means of Nakatani’s electropuncture diagnostics. Chronological age of the group was 63.5±0.7. Before the use of TF the biological age of the group differed from chronological by -4.2 ±0.6 years. The majority of men demonstrated a decrease in the
functional activity of endocrine and of immune systems’ as well as hyperfunction of the liver and of urinary bladder and hypofunction pancreatic.

Results: The study showed that initially disturbed body system functions were significantly normalized. After the course of TF treatment the difference between biological and chronological age was (-8.2) ±0.5 years (p<0.05),>rejuvenation effect of 4 years!



K. HEPATITIS B & C

a) CLINICAL DIAGNOSIS: CHRONIC HEPATITIS C : A.C. , 44 years old, married, female with a history of blood transfusion secondary to massive bleeding when she delivered her third baby in Saudi Arabia. Patient took advantage of health benefits of his son, so she underwent a comprehensive executive check-up.

REMARKABLE FINDINGS:

Physical examinations: hepatomegaly , tenderness on palpation at the right upper quadrant of abdomen;
Diagnostic Tests: Abdominal ultrasound- beginning cirrhotic liver.
Elevated liver enzymes: SGPT, SGOT Hepatitis C- Reactive

CLINICAL DIAGNOSIS: CHRONIC HEPATITIS C

PLAN OF MEDICAL MANAGEMENT:

June 1, 2009: Interferon ∞-2B, 3 MIU (Million international Unit)/vial
Subcutaneous injection for 48 weeks, 1 vial per week

Transfer Factor Tri-Factor, 2 capsule 3x a day

June 30, 2009: After 4 weeks of the said treatment,
Repeat physical exam. Liver size is now normal
Liver enzymes: normal
Hepatitis C : WEAKLY REACTIVE

RESULT: JULY 1, 2009: IN JUST 4 WEEKS, NON-REACTIVE ANTI-HCV


b) CLINICAL DIAGNOSIS : HEPATITIS B, HIGHLY INFECTIOUS : R.G. 23years old, single, male, newly graduate eager to seek employment, eldest of 4 siblings. However on medical examinations, he was found out that he is HEPATITIS B surface Antigen positive. Hence, he is not recommended to be fit to work

HEPATITIS PROFILE WAS REQUESTED TO CONFIRM THE
INFECTIOUSNESS OF THE VIRUS.

Result: HbsAg- Reactive
Anti-HbsAg- Non Reactive
HBeAg –Reactive- (THIS POSITIVITY SHOWS THAT
HE IS HIGHLY INFECTIOUS)
Anti-HCV- non reactive
SGPT, SGOT- ELEVATED

Physical examination: icteresia both eyes, palpable liver edge


DIAGNOSIS: HEPATITIS B, HIGHLY INFECTIOUS

Plan of Management:

June 8, 2009
Interferon ∞-2B, 5 MIU (Million international Unit)/vial
Subcutaneous injection for 48 weeks 3 vials/ week

Transfer Factor Tri-Factor, 2 capsule 3x a day

June 30, 2009: After 3 weeks of the said treatment,
Repeat physical exam. Liver edge is no longer palpable
Liver enzymes: slightly elevated HbeAG: NON- REACTIVE

IN 3 WEEKS, A HIGHLY CONTAGIOUS HEPATITIS B WAS REVERTED TO
NON-INFECTIOUS STATE WHICH IS UNUSUAL.

AUGUST 8, 2009: IN JUST 8 WEEKS PATIENT HAS FULLY RECOVERED with SEROCONVERSION (REACTIVE ANTI-HBs). THIS IS A BREAKTHROUGH , A FIRST IN THE PHILIPPINES BECAUSE ACCORDING TO THE AMERICAN GUIDELINES, THERE IS NO CURE FOR HEPA-B. (TF IS NOT A DRUG NOR A CURE, BUT WHAT HAPPENED HERE IS THAT THE IMMUNE SYSTEM WITH THE HELP OF TF WAS ABLE TO BUILD A CELL-MEDIATED IMMMUNITY CMI AGAINST HEPA-B.

K. KIDNEY TESTIMONIES FROM AROUND THE WORLD

KIDNEY My son has had kidney problems since he was born. This has caused him to be constantly weak and constipated. His urine was also very cloudy. He is now 12 years old and needless to say he has suffered for 12 years. Every 3 days he had to be taken to the hospital to see the doctor. Then, I started him on Transfer Factor - 4 capsules of Advanced Formula and 60ml Riovida each day. 3 weeks later, I noticed a significant improvement. He was going to the toilet daily, and his urine had cleared up. He had more energy and could go out to play with his friends after school. He could also sweat when he could not previously. Before Transfer Factor, I had put him on many different types of medication and food supplements which have never helped. Transfer Factor has changed everything and improved his health. I have full confidence that Transfer Factor is very effective.
Chua Lea Ping, 45 years old, Female, Seremban, Negeri Sembilan, Malaysia.

KIDNEY A couple of weeks ago I got very, very ill--so ill that I had to go to the hospital. I had a tremendous pain in my side and I was pretty sure I had a kidney infection. It usually keeps me down for about 20 days. For a week and a half, I couldn't eat and I threw up and had diarrhea all day long. My husband got in contact with someone who was a distributor at the company and I decided to quit all my other pills and just take transfer factors. The next day, I took nine--three in the morning, three in the afternoon, and three at night. The day after that, I had my first meal. I was grateful that I felt so much better. I really believe it's the transfer factors that have given me the energy that I need. Isabel A.

KIDNEY "My mother, who has suffered with a serious kidney disease for the past 10 years, and tore her Achilles tendon away from the bone around a year ago, began taking transfer factors, along with Fibro AMJ, 7 days ago. She has been taking about 10-12 prescriptions for the above conditions, none of which had helped with her heel problems. Starting on the 4th day of taking the T.F. & Fibro AMJ (A.M.), at the recommended dosage of 3 each per day, she began to notice an improvement. Today, she says it's better than it's been for a very long time, and is reporting that she's also feeling an improvement in her general well-being. She must be, since over the past few days she has vacuumed her house, washed some windows, and washed & waxed her car. That's more activity than I've seen from her in years! Many thanks to everyone involved with these remarkable products. My mother-in-law is starting the same regimen next week. I'll keep you posted on her progress, as well." Jill.

KIDNEY-NEPHROTIC My son Jasper, was diagnosed with nephrotic syndrome (in laymen terms - kidneys not able to sieve protein molecules) when he was 11 months old. He is now 7 years old. His prognosis was not good; his health got worse from year to year. I almost lost him on September 11, 2001 after he went into shock and lost consciousness due to attacks form Chicken Pox and another stomach virus. I was advised by the doctors to improve his immune system, otherwise he will have a high chance of having kidneys failure in 2002. He has been treated with steroids, so much that he had become steroid dependent. The toxicity of steroids can be seen on his face and all over his bloated body. In June of 2002 I started him on TF+, 6 a day. I could see visible results after only 2 weeks. His hairy hands and body became not so hairy. He started to slim down. His daily pee test showed no trace of protein. Since then he is sick less and he recovered from a cough without antibiotics. So far, he has not fallen ill except for 2 times of cough virus attacks. This is unlike the past when I had to visit the doctors for antibiotics every other week. Currently, he is living like any other normal kid. I do not need to control his diet. He was on salt free diet for the past 5 years. CY, Malaysia.

KIDNEY INFECTION The grandmother of my friend was in the hospital with a severe kidney infection. The doctors had planned on putting her on kidney dialysis. My friend gave her Chioce 50 and TF+ while in the hospital. Within days the infection cleared up and the doctors sent her home saying that she does not need the kidney dialysis. My family has taken grapeseed for may years and truly believe in its healing power. We are extremely happy with the products and would recommend them to anyone. Darlene, NC.

KIDNEY FAILURE Originally Cynthia was taken to the emergency room in very serious condition and then she was placed in ICU, where she has remained since then. The head physician didn't see how she could live. The bacteria had ravaged her muscles, liver, pancreas, and kidneys. For at least ten days Cynthia has suffered from kidney failure gaining over 30 pounds since she could not eliminate liquid. They used furosemide to move some of the liquid through her, but the kidneys were not purifying. The kidney marker was up to 12+ and the physician didn't believe there was much chance that the kidneys would ever function again. We talked the physician into using transfer factors after it didn't look like the antibiotics were going to do the job and seemed that the kidneys were to far gone. I am very happy to report that we got word from the hospital today 13 days later that Cynthia is be released tomorrow from the hospital. One of the nurses said, "she had never seen a patient come back from the condition that Cynthia was in, it must have been divine intervention." Of course we cannot know exactly what the total answer was that saved Cynthia's life. Cynthia has been ill for 17 years. Before she had this last event, her body weight was down to 89 pounds so when she was hit by this ravaging infection it was considerably more dangerous. The doctors shared no hope that she could recover, actually just the opposite. Today she is laughing, joking and excited about going home. Was it transfer factors? Was it the wonderful care of the doctors and nurses? Was it prayer? Maybe all three. We are finding over and over again that wonderful things can happen when your immune system is filled with intelligence and working at top efficiency. Thanks for all of your prayers. Kay Bergen for Cynthia Bergen